J Cancer 2019; 10(19):4499-4508. doi:10.7150/jca.31487 This issue

Research Paper

Galangin inhibits epithelial-mesenchymal transition and angiogenesis by downregulating CD44 in glioma

Daliang Chen1*, Dengfeng Li2*, Xiao-bing Xu1*, Shengcong Qiu1, Shi Luo1, Erning Qiu1, Ziyun Rong1, Ji Zhang, Dahai Zheng

1. Department of Neurosurgery, Shunde Hospital, Southern Medical University (The First People,s Hospital of Shunde Foshan), Foshan, China.
2. Department of Neurosurgery, Shanwei People's Hospital, Shanwei, Guangdong, China.
* contributed equally to this work.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Chen D, Li D, Xu Xb, Qiu S, Luo S, Qiu E, Rong Z, Zhang J, Zheng D. Galangin inhibits epithelial-mesenchymal transition and angiogenesis by downregulating CD44 in glioma. J Cancer 2019; 10(19):4499-4508. doi:10.7150/jca.31487. Available from https://www.jcancer.org/v10p4499.htm

File import instruction


Galangin (3,5,7‑trihydroxyflavone), a natural flavonoid present in plants, has been reported to possess anticancer properties in various types of cancers comprising glioma. The underlying mechanism, however, has not been fully elucidated. CD44, a hall marker in glioma, has been reported to be associated with epithelial-mesenchymal transition (EMT) and angiogenesis, which play important roles in glioma progression. In this study, we aimed to investigate whether galangin can inhibit EMT, angiogenesis and CD44 expression in glioma. We observed that galangin inhibited the proliferation, migration, invasion and angiogenesis of glioma cells in a dose-dependent manner, suppressed the expression of CD44 and inhibited angiogenesis of glioma cells through downregulating vascular endothelial growth factor (VEGF) in HUVECs. In addition, the overexpression of CD44 in U87 and U251 cells partly abolished the effects of galangin on glioma cells. Moreover, galangin suppressed tumor growth in an intracranial glioma mouse model. These results indicate that galangin is a potential novel drug for glioblastoma treatment due to its ability to suppress of CD44, EMT and angiogenesis.

Keywords: galangin, EMT, CD44, suppression, glioblastoma